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Research
throughout the Northern Territory, 20%
had tympanic membrane perforation,
despite 87% uptake of pneumococcal con-
jugate vaccine.1 Such high rates of AOM
with p rfo ation (AOMwiP) and chronic
suppurative otitis media (CSOM) are sel-
dom reported in the medical literature. A
Desi
in 16
AOM
or am
doub
2003
Main24 MABSTRACT
Objective:  To compare the clinical effectiveness of single-dose azithromycin treatment 
with 7 days of amoxycillin treatment among Aboriginal children with acute otitis media 
(AOM) in rural and remote communities in the Northern Territory.
gn, setting and participants:  Aboriginal children aged 6 months to 6 years living 
 rural and remote communities were screened for AOM. Those diagnosed with 
 were randomly allocated to receive either azithromycin (30 mg/kg as a single dose) 
oxycillin (50mg/kg/day in two divided doses for a minimum of 7 days). We used a 
le-dummy method to ensure blinding. Our study was conducted from 24 March 
 to 20 July 2005.
 outcome measures:  Failure to cure AOM by the end of therapy; nasal carriage of 
Streptococcus pneumoniae and non-capsular Haemophilus influenzae (NCHi).
Results:  We followed 306 of 320 children (96%) allocated to the treatment groups. 
Single-dose azithromycin did not reduce (or increase) the risk of clinical failure (50% 
failure rate [82/165]) compared with amoxycillin (54% failure rate [83/155]) (risk difference 
[RD], – 4% [95% CI, – 15% to 7%]; P = 0.504). Compared with amoxycillin, azithromycin 
significantly reduced the proportion of children with nasal carriage of S. pneumoniae 
(27% v 63%; RD, – 36% [95% CI, – 47% to – 26%]; P < 0.001) and NCHi (55% v 85%; RD, 
– 30% [95% CI, – 40% to – 21%]; P < 0.001). Nasal carriage of S. pneumoniae with 
intermediate or full resistance to penicillin was lower (but not significantly so) in the 
azithromycin group (10% v 16%), but this group had significantly increased carriage 
of azithromycin-resistant S. pneumoniae (10% v 3%; RD, 7% [95% CI, 0.1% to 12%]; 
P = 0.001). Carriage of β-lactamase-producing NCHi was about 5% in both groups.
Conclusion:  Although azithromycin reduced nasal carriage of S. pneumoniae and 
NCHi, clinical failure was high in both treatment groups. The possibility of weekly 
azithromycin treatment in children with persistent AOM should be evaluated.
Trial registration: 
MJA 2010; 192: 24–29
 Australian Clinical Trials Registry ACTRN 12609000691246.us
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soA tralian Aboriginal children areone to frequent and severe epi-des of acute otitis media (AOM).
In a 2003 survey of over 600 children
living in 29 Aboriginal communities
contributing factor to disease progression
may be failed detection of AOM due to the
absence of acute symptoms (pain, irritabil-
ity or fever) in the presence of a bulging
tympanic membrane.2 Thus, a diagnosis of
AOM without perforation (AOMwoP) is
recommended if a bulging tympanic mem-
brane is present, whether symptoms are
present or not.3 There are few studies
assessing antibiotic treatment in such high-
risk populations.
We have found that, compared with pla-
cebo, long-term antibiotic treatment
resolves middle ear effusion and reduces
perforation.4 However, these regimens are
difficult to deliver effectively,5 particularly to
poor families in remote settings. Previous
studies have shown that short-course azi-
thromycin (for 3–5 days),6-9 weekly single-
dose azithromycin prophylaxis for 12
weeks10 or a single dose of azithromycin11,12
are effective for treating AOM and are less
likely than amoxycillin clavulanate to be
associated with gastrointestinal side effects.8
The primary aim of our study was to
determine the clinical effectiveness of a single
dose of azithromycin compared with a stand-
ard 7-day treatment course of amoxycillin13
in a population at high risk of tympanic
membrane perforation and CSOM.
METHODS
Study design
We conducted a participant-blinded, care
provider-blinded, assessor-blinded, ran-
domised controlled trial — the Azithromy-
cin versus Amoxycillin for Treatment of
Acute Otitis Media in Aboriginal Children
(AATAAC) study — comparing single-dose
azithromycin with 7 days of twice-daily
amoxycillin treatment. Treatment allocation
was stratified by health centre, body weight
and diagnosis (AOMwoP or AOMwiP),
using randomly varying block sizes.
Participants
Our study commenced on 24 March 2003
and was completed on 20 July 2005. We
screened Aboriginal children from 14
remote communities and two Aboriginal
medical services in northern and central
Australia. Our inclusion criteria were (a) age
between 6 months and 6 years; (b) new
diagnosis of AOMwoP or AOMwiP; and (c)
willingness of parents to bring their child for
a follow-up visit. Children were excluded if
they had (a) previously been allocated to an
intervention group in the same study; (b)
received antibiotics in the previous 7 days;
Abbreviations
AOM Acute otitis media
AOMwiP Acute otitis media with (tympanic 
membrane) perforation
AOMwoP Acute otitis media without 
(tympanic membrane) 
perforation
CSOM Chronic suppurative otitis media
MIC Minimum inhibitory 
concentration
NCHi Non-capsular Haemophilus 
influenzae
RD Risk differenceJA • Volume 192 Number 1 • 4 January 2010
RESEARCH(c) current severe illness requiring intrave-
nous or intramuscular antibiotic treatment
to be given within the following 7 days; (d) a
known allergy to penicillin or azithromycin;
or (e) perforation covering more than 2% of
the tympanic membrane.
Interventions
Children with AOM were randomly allo-
cated to receive either azithromycin (30 mg/
kg as a single dose) and amoxycillin pla-
cebo, or amoxycillin (50 mg/kg/day in two
divided doses for a minimum of 7 days) and
azithromycin placebo. All children were
scheduled to be examined on Day 0 and at
the end of therapy (between Day 6 and Day
11). Children diagnosed with AOMwiP at
the end of therapy received a second course
of treatment and were also examined
between Day 12 and Day 21.
Outcomes
Primary outcomes
In our clinical trial protocol, we pre-
specified two primary outcomes:
• Clinical failure: the proportion of children
with persistent ear pain, a bulging tympanic
membrane or middle ear discharge at the
end of therapy (children lost to follow-up
were assumed not to have improved); and
• Failure to improve: the proportion of
examined children with no improvement in
clinical signs at the end of therapy. Improve-
ment in clinical signs was determined by
healing of a tympanic membrane perforation
or substantial reduction in tympanic mem-
brane bulging. Improvement could occur
despite clinical failure at end of therapy.
Secondary outcomes
We also compared the azithromycin and
amoxycillin groups with regard to the fol-
lowing secondary outcomes:
• Clinical outcomes: the proportion of chil-
dren with clinical failure or failure to
improve when seen before Day 11 after
commencement of therapy (per-protocol
analysis); clinical failure according to base-
line diagnosis (AOMwoP or AOMwiP); clin-
ical failure according to age (< 2 years or  2
years); clinical failure according to nasal
carriage of otitis media pathogens (Strepto-
coccus pneumoniae or non-capsular Haemo-
philus influenzae [NCHi]) at the end of
therapy; and additional clinical observations
(runny nose and skin sores). We also
recorded new episodes of AOMwiP or pain.
• Microbiological outcomes: nasal carriage of
S. pneumoniae, NCHi, resistant S. pneumo-
niae or β-lactamase-positive NCHi; and the
proportion of ear discharge cultures positive
for S. pneumoniae or NCHi.
Clinical assessment
All clinical assessments were made by ear
health research officers. Otoscopic findings
were recorded on a standardised form.
Assessments were made using a GSI 38
tympanometer (Grason-Stadler, Eden Prai-
rie, Minn, USA), a LumiView portable bin-
ocu la r  mic roscope  (Welch  A l lyn ,
Skaneateles Falls, NY, USA), a Siegle specu-
lum for pneumatic otoscopy, and a video-
otoscope (Welch Allyn, Skaneateles Falls,
NY, USA). Video recordings of the tympanic
membranes were reviewed by an independ-
ent unblinded observer.
We categorised middle ear states into one
of six diagnostic categories, using criteria
based on recommendations for clinical prac-
tice in this population:3
• Normal;
• Otitis media with effusion (intact and
non-bulging tympanic membrane and type
B tympanogram);
• AOMwoP (any bulging of the tympanic
membrane and type B tympanogram);
• AOMwiP (middle ear discharge observed
and perforation recently healed or present
for less than 6 weeks or covering less than
2% of the pars tensa of the tympanic mem-
brane [CSOM is nearly always associated
with larger perforations]);
• Dry perforation (tympanic membrane
perforat ion without any discharge
observed); or
• CSOM (middle ear discharge observed
and perforation present for longer than 6
weeks and covering at least 2% of the pars
tensa of the tympanic membrane).
The final middle ear diagnosis reflected
the child’s more severely affected ear (high-
est category).
The presence of nasal discharge was
recorded if nasal discharge was visible from
1 metre away at any time during the clinical
examination. Skin sores (raised crust or pus
visible) were recorded if visible on the arms,
legs or head.
Microbiology
Nasal swabs were taken at baseline and at
follow-up examinations. Swabs of ear dis-
charge were also collected on the days when
nasal swabs were taken. All swabs were col-
lected, transported, stored and cultured as
previously described.14 Azithromycin resist-
ance was defined as a minimum inhibitory
concentration (MIC) of 2μg/mL. High-level
resistance was defined as MIC >32μg/mL.
Sample size
We estimated that in at least 50% of children
receiving standard therapy for AOM the
condition would fail to resolve within 8
days. With 150 children in each interven-
tion arm, the study would have a power of
95% to detect an improved outcome in an
additional 20% of children ( = 0.05). This
difference was chosen as the minimum
improvement that would potentially result
in a change in recommended therapy for
AOM from amoxycillin to azithromycin.
All statistical analyses were conducted
using Stata software, version 10 (StataCorp,
College Station, Tex, USA). Assessment of
statistical significance was based on the
Fisher exact test.
Ethics approval and registration
Our study was approved by the human
research ethics committees of the Menzies
School of Health Research and the Royal
Darwin Hospital and by the Central Austral-
ian Human Research Ethics Committee, and
was registered with the Australian Clinical
Trials Registry (ACTRN 12609000691246).
An independent Data and Safety Monitoring
Board chaired by Professor David Brewster
and Associate Professor Alan Ruben of the
NT Clinical School, Flinders University,
reviewed the data.
RESULTS
Clinical observations, nasal carriage 
and ear discharge at baseline (Box 1)
Clinical observations. Of 320 children taking
part in the trial, 165 were randomly allocated
to the azithromycin treatment group and 155
to the amoxycillin treatment group. As seven
children were lost to follow-up in each
group, analysis was carried out on the
remaining 306 children (Box 2). Most were
less than 2 years of age, and about half were
male. For each group at baseline, 85% had
AOMwoP and 15% had AOMwiP, and 5% of
mothers reported that they thought their
child had ear pain. Nasal discharge was seen
in 69% of children and skin sores in 6%–7%.
Nasal carriage. For both treatment groups,
nasal carriage of S. pneumoniae and NCHi was
83% or more. About 14% of children were
colonised by S. pneumoniae with intermediate
or full resistance to penicillin (MIC 0.12μg/
mL), and about 5% carried azithromycin-
resistant S. pneumoniae (MIC 2μg/mL). Less
than 10% of children swabbed carried β-
lactamase-producing NCHi.MJA • Volume 192 Number 1 • 4 January 2010 25
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amoxycillin groups, respectively, S. pneumo-
niae was cultured from 22% and 32% of ear
discharge swabs, and NCHi from 36% and
41% of ear discharge swabs.
Clinical outcomes, nasal carriage and 
ear discharge cultures at the end of 
therapy
Clinical failure (Box 3). At the end of therapy,
50% of the azithromycin group and 54% of
the amoxycillin group were clinical failures.
Similar proportions (45% and 49%) failed to
improve, and about 5% were worse in both
groups (nine children developed new perfo-
rations). Differences between the azithromy-
cin and amoxycillin groups in clinical failure
rates were not significant.
No differences in clinical failure or failure
to improve were indicated in a per-protocol
analysis (children seen before Day 11 after
commencement of treatment). Only four
parents reported that their child had ear
pain (three of the children were in the
amoxycillin group). Fewer children in the
azithromycin group than the amoxycillin
group had runny nose (35% v 46%), but the
difference was not significant, and about 4%
of children in both groups had skin sores.
Clinical failure rates in children who had
AOMwoP at baseline were 40% in the azi-
thromycin group and 46% in the amoxycillin
group. For children who had AOMwiP at
baseline, clinical failure rates were 92% and
83%, respectively. (Clinical failure rates were
84% and 63%, respectively, at Day 12–21.)
There was no significant association
between age group (< 2 years or  2 years)
and clinical failure.
No significant difference in clinical fail-
ure was detected between azithromycin
and amoxycillin groups for carriers or non-
carriers of S. pneumoniae or NCHi at the end
of therapy. Carriage of resistant S. pneumo-
niae or NCHi at baseline did not predict
greater clinical failure. The risk difference
(RD) in clinical failure between children
carrying susceptible organisms (S. pneumo-
niae or NCHi) at baseline and those carrying
resistant organisms at baseline was – 9%.
Complications and side effects. There were three
serious adverse events that resulted in admis-
sion to hospital during the treatment period.
The independent Data and Safety Monitoring
Board found that these were not associated
with the study interventions. No side effects
(eg, allergic, gastrointestinal) led to cessation
of treatment or withdrawal from the study.
New episodes of disease. In both groups, new
perforations were detected in 3%–4% of
children who had AOMwoP at baseline.
Pain resolved in all children who had had
pain at baseline, but four children devel-
oped “new” pain (Box 4).
Nasal carriage. Compared with children in the
amoxycillin group, children in the azithromy-
cin group had significantly lower carriage of
S. pneumoniae and H. influenzae, lower car-
riage of S. pneumoniae with intermediate or
full resistance to penicillin (RD, – 6% [but
this difference was non-significant]), and sig-
nificantly higher carriage of azithromycin-
resistant S. pneumoniae (RD, 7%) (Box 5).
Ear discharge. The proportion of ear dis-
charge cultures that were positive for S.
pneumoniae and NCHi was about 25 per-
centage points lower in the azithromycin
group (Box 5).
Comparison between baseline and end 
of therapy (Box 1 and Box 5)
Compared with baseline, nasal carriage of S.
pneumoniae was significantly lower in both
groups at follow-up (azithromycin group
RD, – 56% [95% CI, – 65% to – 47%]), and
carriage of NCHi was also significantly
reduced (azithromycin group RD, – 31%
[95% CI, – 40% to – 21%]). In the azithro-
mycin group, compared with baseline, car-
1 Baseline characteristics of children participating in our study
Characteristic
Azithromycin group 
(n = 165)
Amoxycillin group 
(n = 155)
Mean age in months (SD) 18 (11) 17 (12)
Age less than 2 years 125/165 (76%) 125 (81%)
Male 80/165 (48%) 89 (57%)
Clinical features
Ear pain 9/165 (5%) 8 (5%)
AOMwoP 140/165 (85%) 131 (85%)
AOMwiP 25/165 (15%) 24 (15%)
Nasal discharge 114/165 (69%) 107 (69%)
Skin sores 11/165 (7%) 10 (6%)
Nasal carriage of otitis media pathogens*
Streptococcus pneumoniae 136/164 (83%) 131/152 (86%)
NCHi 140/164 (85%) 129/152 (85%)
Any S. pneumoniae or NCHi 155/164 (95%) 144/152 (95%)
Resistant S. pneumoniae
Penicillin (MIC  0.12 μg/mL) 25/164 (15%) 20/152 (13%)
Azithromycin (MIC  2 μg/mL) 8/164 (5%) 6/152 (4%)
Any resistant S. pneumoniae 31/164 (19%) 22/152 (14%)
β-lactamase-producing NCHi 15/164 (9%) 9/152 (6%)
Any resistant S. pneumoniae or NCHi 42/164 (26%) 29/152 (19%)
Culture of ear discharge from children with AOMwiP†
S. pneumoniae 8/36 (22%) 11/34 (32%)
NCHi 13/36 (36%) 14/34 (41%)
AOM = acute otitis media. AOMwiP = AOM with (tympanic membrane) perforation. AOMwoP = AOM 
without (tympanic membrane) perforation. MIC = minimum inhibitory concentration. NCHi = non-capsular 
Haemophilus influenzae. * Figures are proportion (%) of children swabbed. † Figures are proportion (%) of ears 
swabbed. ◆
2 Flowchart of children enrolled in 
the study
Randomisation (n = 320)
Azithromycin (n = 165)
Diagnosis at baseline:
AOMwoP (n = 140)
AOMwiP (n = 25)
Diagnosis at baseline:
AOMwoP (n = 134)
AOMwiP (n = 24)
Lost to 
follow-up 
(n = 7)
Amoxycillin (n = 155)
Diagnosis at baseline:
AOMwoP (n = 131)
AOMwiP (n = 24)
Diagnosis at baseline:
AOMwoP (n = 125)
AOMwiP (n = 23)
Lost to 
follow-up 
(n = 7)End of 
therapy 
follow-up26 MJA • Volume 192 Number 1 • 4 January 2010
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full resistance to penicillin was lower at
follow-up (10%) than at baseline (15%)
(RD, – 5% [95% CI, – 12% to 2%]). In
contrast, nasal carriage of azithromycin-
resistant S. pneumoniae was higher at follow-
up (10%) than at baseline (5%) (RD, 5%
[95% CI, – 1% to 10%]).
DISCUSSION
To our knowledge, this is the first ran-
domised controlled trial of antibiotic treat-
ment of AOM in a population with high
rates of acute and chronic tympanic mem-
brane perforation. Although our study was
not designed or powered to show equiva-
lence, our findings suggest that the two
antibiotic regimens are likely to have similar
efficacy in this population. However, in view
of the substantial problems of adherence to
twice-daily regimens in such populations,
single-dose azithromycin treatment may be
a more appropriate standard treatment
option than a 7-day course of amoxycillin.
Azithromycin treatment reduced nasal
carriage of both S. pneumoniae and NCHi.
Although overall rates of antibiotic resistance
were unchanged, azithromycin treatment
was associated with an increase in carriage of
azithromycin-resistant S. pneumoniae.
In other published trials, an evidence
summary and a meta-analysis that included
azithromycin treatment of AOM, clinical
response rates in groups receiving azithro-
mycin have generally been 70% or higher.6-
8,11,12,15-18 In a Cochrane review of short-
course antibiotic treatment for AOM, out-
comes of short courses of agents such as
ceftriaxone or azithromycin were compara-
ble with outcomes of longer courses of other
antibiotics.8 Clinical trials assessing out-
comes of single-dose azithromycin
treatment11,12 have reported similarly high
success rates. The Cochrane meta-analysis
summary odds ratio for primary outcomes
after 3–5 days’ treatment with azithromycin
(n = 1347) compared with 10 days’ treat-
ment with another antibiotic (n = 1246) was
1.09 (95% CI, 0.86 to 1.38). Success rates
were about 86% in both azithromycin
groups and comparison groups.8 In a single
trial that reported outcome data for perfo-
rated or non-perforated eardrums of 28
evaluable patients with spontaneous perfo-
ration, there were more failures after 5 days
of therapy than after 10 days of therapy.19
In our study, clinical success rates among
Aboriginal children receiving azithromycin
therapy for AOM were much lower than the
rates reported in previous published stud-
3 Clinical outcomes at the end of therapy (between Day 6 and Day 11)
Azithromycin 
group
(n = 165)
Amoxycillin 
group
(n = 155) RD (95% CI) P
Primary outcomes (intention-to-treat analysis)
Clinical failure 82/165 (50%) 83/155 (54%) – 4% (– 15% to 7%) 0.504
Failure to improve 71/158 (45%) 72/148 (49%) – 4% (– 15% to 7%) 0.567
No change 63/158 (40%) 63/148 (43%)
Worse 8/158 (5%) 9/148 (6%)
Primary outcomes (per-protocol analysis*)
Clinical failure 66/140 (47%) 72/135 (53%) – 6% (– 18% to 6%) 0.335
Failure to improve 62/140 (44%) 68/135 (50%) – 6% (– 18% to 6%) 0.335
Other clinical outcomes
Pain 1/156 (1%) 3/147 (2%) – 1% (– 4% to 1%) 0.358
Runny nose 55/158 (35%) 67/146 (46%) – 11% (– 22% to 0.1%) 0.06
Skin sores 7/158 (4%) 4/146 (3%) 2% (– 3% to 6%) 0.545
Clinical failure according to baseline diagnosis
AOMwoP at baseline 53/134 (40%) 57/125 (46%) – 6% (– 18% to 6%) 0.379
AOMwiP at baseline 22/24 (92%) 19/23 (83%) 9% (– 10% to 28%) 0.416
Clinical failure according to age
< 2 years of age 61/125 (49%) 68/125 (54%) – 6% (– 18% to 7%) 0.448
 2 years of age 21/40 (53%) 15/30 (50%) 3% (– 21% to 26%) 1.000
Clinical failure according to nasal carriage of otitis media pathogens at the end of therapy
Positive for Streptococcus 
pneumoniae
21/42 (50%) 52/92 (57%) – 7% (– 25% to 12) 0.575
Negative for S. pneumoniae 53/115 (46%) 23/53 (43%) 3% (– 13 to 19%) 0.868
Positive for NCHi 46/86 (53%) 69/124 (56%) – 2% (– 16% to 12%) 0.779
Negative or NCHi 28/71 (39%) 6/21 (29%) 11% (– 12% to 33%) 0.446
Nasal carriage of otitis 
media pathogens at 
baseline (both treatment 
groups combined)
Susceptible 
pathogens at 
baseline†
Resistant 
pathogens at 
baseline‡
S. pneumoniae 124/255 (49%) 27/51 (53%) – 4% (– 19% to 11%) 0.646
S. pneumoniae or NCHi 112/237 (47%) 39/69 (57%) – 9% (– 23% to 4%) 0.218
AOM = acute otitis media. AOMwiP = AOM with (tympanic membrane) perforation. AOMwoP = AOM 
without (tympanic membrane) perforation. NCHi = non-capsular Haemophilus influenzae. RD = risk 
difference. * Assessed before Day 11 after commencement of therapy. † Clinical failure rates in children 
carrying susceptible pathogens at baseline. ‡ Clinical failure rates in children carrying resistant pathogens at 
baseline. ◆
4 Persistent and new episodes of acute otitis media (AOM) at the end of 
therapy (between Day 6 and Day 11)
Azithromycin 
group (n=165)
Amoxycillin 
group (n=155) RD (95% CI) P
AOMwoP if AOMwoP at baseline 49/140 (35%) 52/131 (40%) – 5% (– 16% to 7%) 0.452
AOMwiP if AOMwiP at baseline 14/25 (56%) 11/24 (46%) 10% (– 18% to 38%) 0.572
AOMwiP if no AOMwiP at baseline 4/140 (3%) 5/131 (4%) – 1% (– 5% to 3%) 0.743
Pain if pain at baseline 0/9 0/8
Pain if no pain at baseline 1/156 (1%) 3/147 (2%) – 1% (– 4% to 1%) 0.358 
AOMwiP = AOM with (tympanic membrane) perforation. AOMwoP = AOM without (tympanic membrane) 
perforation. RD = risk difference. ◆MJA • Volume 192 Number 1 • 4 January 2010 27
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for patients with azithromycin-resistant S.
pneumoniae (67%) compared with those
with susceptible S. pneumoniae (90%).17 The
rates of antimicrobial resistance found in
our study (about 21%) do not explain the
high proportion of clinical failures observed.
Poor adherence to recommended treat-
ment regimens could explain poor clinical
outcomes in the amoxycillin group. How-
ever, as the single dose of azithromycin was
given under supervision, compliance with
azithromycin treatment was close to 100%.
In another of our studies in which compli-
ance with twice-daily amoxycillin therapy
was monitored, we estimated that 17/30
participants took less than half their recom-
mended treatment.20 In that study, we found
that AOM persisted in about three-quarters
of participants and could not be explained
by nasopharyngeal carriage of penicillin-
resistant S. pneumoniae strains.20
The poor clinical outcomes associated
with failure to eradicate NCHi in our study
are consistent with clinical and bacteriologi-
cal studies by Dagan et al showing clinical
failure rates of 65%18 and 53%21 in patients
with NCHi infections receiving azithromy-
cin treatment.
We believe that persistent ear disease is
related to high bacterial load in the naso-
pharynx.22 Antibiotics that eradicate otitis
media pathogens and reduce bacterial load
are needed for clinical success. While azithro-
mycin was more effective at eradicating AOM
pathogens than amoxycillin, nasal carriage of
any S. pneumoniae or NCHi remained high at
the end of therapy (65% in the azithromycin
group and 92% in the amoxycillin group).
For children with AOMwiP, ear discharge
cultures were less likely to be positive after
treatment with azithromycin. The observed
association of better clinical outcomes with
pathogen clearance and the greater impact of
azithromycin on carriage (particularly for
NCHi) led us to believe that clinical trials of
longer courses of azithromycin treatment are
required. The potential benefits for other
important child health problems (eg, skin
sores, runny nose and trachoma) should also
be evaluated.
In the AATAAC study, most children with
AOM at enrolment had an intact bulging
tympanic membrane. However, as few had
ear pain, it is likely that many children in
this population will have undiagnosed
AOM. This may explain the high rate of
tympanic membrane perforation in this
population. Further research is needed to
determine the benefits of early detection of
at-risk children as well as predictors of
which children will progress to perforation.
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S. pneumoniae and NCHi 26/157 (17%) 82/146 (56%) – 40% (– 50% to – 30%) < 0.001
Any S. pneumoniae or NCHi 102/157 (65%) 134/146 (92%) – 27% (– 36% to – 18%) < 0.001
Resistant S. pneumoniae*
Penicillin (MIC 0.12μg/ml) 16/157 (10%) 23/146 (16%) – 6% (– 13% to 2%) 0.171
Azithromycin (MIC 2 μg/mL) 15/157 (10%) 5/146 (3%) 7% (0.1% to 12%) 0.001
Azithromycin (MIC 32 μg/mL) 9/157 (6%) 3/146 (2%) 4% (– 1% to 8%) 0.140
Any resistant S. pneumoniae 25/157 (16%) 26/146 (18%) – 2% (– 10% to 7%) 0.749
β-lactamase-producing NCHi 8/157 (5%) 7/146 (5%) 0.3% (– 4% to 5%) 1.0
Any resistant S. pneumoniae or 
NCHi
33/157 (21%) 32/146 (22%) – 1% (– 10% to 8%) 0.889
Culture of ear discharge from children with AOMwiP†
S. pneumoniae 0/27 6/24 (25%) – 25% (– 40% to – 3%) 0.040
NCHi 6/27 (22%) 12/24 (50%) – 28% (– 53% to – 2%) 0.046
AOMwiP = acute otitis media with (tympanic membrane) perforation. NCHi = non-capsular Haemophilus 
influenzae. RD = risk difference. * Figures are proportion (%) of children swabbed. † Figures are proportion (%) 
of ears swabbed. ◆28 MJA • Volume 192 Number 1 • 4 January 2010
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